For readers interested in the application of biomarkers, here's a Review on biomarker-guided decision making in drug development for neurodegenerative disorders rdcu.be/e3jHt nature.com/articles/s41...

The Biomarkers Consortium: 20 years of advancing precision medicine nature.com/articles/d41... This article highlights contributions from the FNIH Biomarkers Consortium in advancing biomarkers to enable disease monitoring, earlier interventions and improved outcomes

For readers interested in new drugs for chronic obstructive pulmonary disease, this Review article in the February issue analyses progress in the field and drugs in the pipeline such as PDE3/4 inhibitors rdcu.be/e27dW nature.com/articles/s41...

This article in the February issue analyses M&As and partnerships in the biopharma industry in 2025, with GSK's potential $12.5 billion partnership with Hengrui Pharmaceuticals focused on a PDE3/4 inhibitor for COPD in the top spot for licensing deals nature.com/articles/d41...

Review @natrevdrugdiscov.nature.com @grieshaber.bsky.social @biohacker.bsky.social Roads and detours for CAR T cell therapy in autoimmune diseases www.nature.com/articles/s41...

I'm thrilled to start my first bluesky post by highlighting the review paper Hyerim and I have been working really hard together - published just yesterday on Nature Reviews Drug Discovery. In this review, we outlined the latest ecDNA biology and corresponding therapeutic vulnerabilities [1/2] -

Our February issue is live! Read about in vivo CAR-T cell therapy, new drugs for chronic obstructive pulmonary disease, quantitative systems toxicology, last year's drug approvals and more here www.nature.com/nrd/volumes/...

The 2025 FDA approvals: one count is holding up fine, another maybe not:

Targeting extrachromosomal DNA in human cancers www.nature.com/articles/s41... rdcu.be/e2kVS This new Review discusses ecDNA biology, challenges faced by current therapeutic and detection approaches and discoveries that highlight emerging therapeutic vulnerabilities

Cobenfy, the first drug with a new mechanism for schizophrenia in decades, is also being investigated in Alzheimer disease. For readers interested in drugs such as this that target muscarinic acetylcholine receptors, here's a review www.nature.com/articles/s41... rdcu.be/e1VOo

“We want to raise the bar and try to really change the outcome of this disease." Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s www.statnews.com/2026/02/02/b...

Strategies for blood–brain barrier (BBB) rejuvenation and repair www.nature.com/articles/s41... rdcu.be/e1ucS BBB dysfunction is a hallmark of diseases including Alzheimer disease and stroke. This new Review discusses therapeutic approaches to BBB repair and protection

Hunting for biopharma’s innovation sweet spot www.nature.com/articles/d41... William Pao — a former chief development officer at Pfizer and head of Roche pharma research and early development — discusses the back stories behind breakthrough therapeutic innovations.

This Review in the January issue discusses how microfluidics, microelectronics and microscaffolds can be used to accelerate the discovery and translation of immunotherapies such as monoclonal antibodies and engineered immune cells www.nature.com/articles/s41... rdcu.be/e09JS

For readers interested in GLP-1-based therapies for obesity and beyond, such as Roche's candidate CT-388, here's a comprehensive review nature.com/articles/s41... rdcu.be/e09xH

Swiss pharmaceutical company Roche said that a once-weekly injection of an experimental drug known as CT-388 helped patients shed weight in a midstage clinical trial—resulting in a weight loss of 22.5% when adjusting for placebo at 48 weeks. on.wsj.com/4ai0mwc

Roads and detours for CAR T cell therapy in autoimmune diseases www.nature.com/articles/s41... rdcu.be/e0XUz This new Review overviews the role of B cells in autoimmunity, and discusses clinical trials and preclinical studies of CAR-T cell therapies for autoimmune disorders

For readers interested in drugs targeting members of the TNF and TNFR superfamilies such as OX40L (the target of amlitelimab) for treating immuno-inflammatory disorders such as atopic dermatitis, here's a comprehensive review nature.com/articles/s41... rdcu.be/e0OhB

Biopharma dealmaking in 2025 www.nature.com/articles/d41... This article analyses trends for mergers and acquisitions (M&As) and partnerships last year, highlighting key deals

Among the FDA approvals was the first antibody-mimetic adnectin - lerodalcibep, a lipid-lowering PCSK9 blocker. Find out more about its history and the adnectin platform here www.nature.com/articles/d41...

For more on new drug approvals by the FDA in 2025, here's our annual round-up by Asher Mullard, including a full list of the drugs and breakdowns by therapeutic area and modality www.nature.com/articles/d41...

The volume of new drugs approved by the FDA in 2025 was similar to the previous year, but their projected commercial value remains below average - find out more in this annual analysis from BCG www.nature.com/articles/d41...

For readers interested in novel drugs for chronic obstructive pulmonary disease, such as PDE3/4 inhibitors underlying recent major deals, here's a recent review www.nature.com/articles/s41... rdcu.be/eZUN4

China's Haisco Licenses COPD Drug to AirNexis for Up to USD1.1 Billion www.yicaiglobal.com/news/chinas-...

Synthetic lethality in cancer drug discovery: challenges and opportunities www.nature.com/articles/s41... rdcu.be/eZng7 PARP inhibitors have been very successful, but clinical translation of other synthetic lethal interactions has been challenging. This Review in the January issue discusses why.

RNA modification systems as therapeutic targets www.nature.com/articles/s41... rdcu.be/eZdRG This Review in the January issue discusses the disease associations of proteins that regulate RNA modifications and advances in the development of therapeutic inhibitors

Our January issue is live - read about synthetic lethality in cancer drug discovery, RNA modification systems as therapeutic targets, microsystem technologies to accelerate the discovery of immunotherapies and more here www.nature.com/nrd/volumes/...

Betting on β-catenin inhibitors in oncology nature.com/articles/d41... The WNT–β-catenin pathway is often overactive in cancer. This news article in the January issue discusses emerging therapeutic inhibitors including stabilized peptides, condensate modulators and degraders

Novel drug treatments for schizophrenia www.nature.com/articles/s41... rdcu.be/eYk7Q This new Review covers promising drug targets for schizophrenia treatment that affect neurotransmitter systems, immune processes and inflammation

2025 FDA drug approvals nature.com/articles/d41... The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency. Read about the trends and highlights, and see the full list of approved therapeutics in our annual round up

Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications nature.com/articles/s41... rdcu.be/eXDui This new Review discusses recent advances in JAK and STAT inhibitor development and highlights emerging therapeutic indications

2025 FDA drug approvals nature.com/articles/d41... The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency. Read about the trends and highlights, and see the full list of approved therapeutics in our annual round up

Analysis of phase II and phase III clinical trial terminations from 2013 to 2023 www.nature.com/articles/d41... This new article analyses trials terminated before completion by sponsors, highlighting strategy/business reasons as a driver of an overall increase in annual terminations

Trends in target novelty in oncology R&D nature.com/articles/d41... This new article analyses the novelty of targets being investigated in oncology drug R&D, and reveals that the majority of late-stage oncology drugs do not have a novel target

Betting on β-catenin inhibitors in oncology www.nature.com/articles/d41... The WNT–β-catenin pathway is often overactive in cancer. Can emerging drugs — including stabilized peptides, condensate modulators and degraders — safely and effectively tamp it back down?

How multispecific molecules are transforming pharmacotherapy rdcu.be/eUp4U nature.com/articles/s41... This article in the December issue discusses how drugs designed to engage two or more entities are overcoming development barriers such as toxicity and redundancy

For readers interested in GLP-1-based therapies for metabolic diseases and beyond, here's a recent review rdcu.be/eT39F nature.com/articles/s41...

Top product forecasts for 2026 nature.com/articles/d41... The top ten best-selling drugs are projected to generate sales of US$198 billion in 2026, driven by the GLP-1-based products for metabolic diseases. Find out more in this new article.

For readers interested in genome editing therapeutics, this Review in the December issue discusses progress in the application of CRISPR-based genome editing to treat inherited blood disorders such as sickle cell disease rdcu.be/eTR9i www.nature.com/articles/s41...

For readers interested in drugs targeting TNF superfamily members such as APRIL and their receptors, here's a comprehensive review rdcu.be/eTG0e www.nature.com/articles/s41...

First-in-class APRIL inhibitor secures approval for rare kidney disease www.nature.com/articles/d41...

For readers interested in drug repurposing, this article overviews computational approaches to drug repurposing and evaluates available in silico resources rdcu.be/eSY57 www.nature.com/articles/s41...

Stimulating medicines repurposing in the EU: a pilot project nature.com/articles/d41... This new article discusses a project testing a framework to support not-for-profit organizations and academia to generate the evidence needed for a regulatory submission of a repurposed drug

The FDA recently approved the 100th small-molecule kinase inhibitor, a quarter of a century on from the landmark approval of imatinib. Read about progress and the key trends in the field in this article in the December issue www.nature.com/articles/d41...

Our December issue is live! Read about how multispecific molecules are transforming pharmacotherapy, CRISPR-based genome editing for blood disorders, advances in the treatment of lupus, progress with small-molecule kinase inhibitors and more here www.nature.com/nrd/volumes/...

Chemical modifications can improve the stability, efficiency and specificity of RNA therapeutics, while reducing their immunogenicity - find out more in this review rdcu.be/eSyD6 www.nature.com/articles/s41...

Excellent review on induced proximity-based therapeutic modalities! Thank you, @dannomura.bsky.social, for featuring our work in the "Targeted Protein Subcellular Localization" section and in Fig. 8!

Happy to share this landscape analysis from Novartis #GlobalHealth colleagues published in @natrevdrugdiscov.nature.com exploring 2 decades of data on approvals, clinical dev. trends, and modalities across 40 diseases with major GH implications. www.nature.com/articles/d41...

For readers interested in drug development for malaria, here's a review covering strategies to combat drug resistance in malaria, HIV and tuberculosis rdcu.be/eRVfv www.nature.com/articles/s41...

Novel antimalarial passes key phase III test www.nature.com/articles/d41... Novartis’s ganaplacide plus lumefantrine (GanLum) is as effective as standard-of-care artemether plus lumefantrine (Coartem) for acute, uncomplicated malaria due to P. falciparum